Pancreatic Cancer
CSHL has several researchers working on pancreatic cancer. David Tuveson, M.D., Ph.D., Professor, directs the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL.
Lustgarten Foundation Pancreatic Cancer Research Laboratory
The Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, led by David Tuveson, M.D., Ph.D. is centered on early detection, drug development and drug delivery. The research will focus initially on three key aspects of pancreatic cancer:
- Developing ways to detect pancreatic cancer early—The presence of cancer in the pancreas causes changes in a person’s system that may be detected in bodily fluids, such as blood or urine. These changes will be identified so that they can be used to routinely test patients for the presence of pancreatic cancer in its earliest stages.
- Identifying new targets for drug development—New pathways will be explored that could potentially uncover new therapeutic approaches for drug development to kill and eliminate pancreatic cancers.
- Using more effective approaches to deliver drugs directly to pancreatic cancers—Existing research shows that pancreatic tumors are difficult to penetrate with chemotherapy, so new methods will be developed to ensure that the chemotherapy reaches the tumor for more effective treatment.
In addition to directing the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, Dr. Tuveson is also the Director of Research for the . In this capacity, he oversees the development of fundable research and works with the Foundation’s Pancreatic Cancer Research Consortium of six, world-renowned medical institutions to identify, prioritize and develop targeted research aimed at ultimately finding a cure for this deadly disease.
- , Ph.D.
- Douglas Fearon, Ph.D.
- David Tuveson, M.D., Ph.D.
At the Lab Season 1 Research Rewind: Cancer
October 8, 2024
As the first season of our new podcast winds down, we’re revisiting all of our episodes with a focus on CSHL’s cutting-edge cancer research.
Old chemo drug, new pancreatic cancer therapy?
August 26, 2024
CSHL scientists have found that folinic acid makes immunotherapy therapy more effective against pancreatic ductal adenocarcinoma in mice.
How to stop cancer cachexia? Start at the top
July 8, 2024
Professor Bo Li and a team of collaborators from four CSHL labs have discovered a new potential drug target for the lethal wasting disease.
At the Lab Episode 13: A more sustainable chemistry
July 2, 2024
For this week’s podcast, CSHL Professor John Moses bridges the gap between chemistry and biology in less than three minutes.
Pancreatic cancer’s cellular amnesia
June 17, 2024
New study from CSHL Professor Christopher Vakoc and former postdoc Diogo Maia-Silva shows how basal-like cancer cells lose their original identity.
Tour CSHL’s Foundations for the Future project
May 9, 2024
Join New York Governor Kathy Hochul and CSHL President & CEO Bruce Stillman for an aerial tour of CSHL’s Foundations for the Future expansion project.
Governor Hochul announces $15 million for CSHL expansion
May 9, 2024
The funding will help pay for a new pancreatic cancer center—part of CSHL’s Foundations for the Future project.
Tuveson elected to American Academy of Arts & Sciences
April 24, 2024
CSHL Cancer Center Director and Professor David Tuveson joins an elite membership roster whose historic ranks include names like Darwin and Einstein.
Click, click, boom—150 new molecules
April 4, 2024
CSHL Professor John Moses premieres an expansive line of new click chemistry products, uncovering leads for better antibiotics and cancer drugs.
One Experiment: Pancreatic mucus
March 26, 2024
That’s not the Starship Enterprise burning up in space. It’s an up-close look at precancerous pancreatic lesions and the mucus they produce.